VACCINE DIRECTED TO INDUCTION OF IMMUNE RESPONSE TO PROTEIN AND GLYCOLIPID ANTIGENS OF BACTERIAL CELLS THROUGH INTERACTION OF CD40L/CD40 RECEPTOR AXIS WITH COMPLEX OF GLYCOLIPID/CD1d RECEPTOR IN NKT CELLS AND IN DENDRITIC CELLS

ABSTRACT

A combination of components to promote an innate and adaptive immune response comprising of a TAA/ecdCD40L vaccine and a complex between the CD1d receptor and an alpha galactosyl ceramide like glycolipid (AGCLGL), to activate NKT cells and activate the CD40 receptor on the DCs and increase the level of the adaptive immune response induced by the TAA/ecdCD40L vaccine to the TAA. The result and advantage of using both the TAA/ecdCD40L vaccine and the α-galactosylceramide-CD1d complex (or a related bacterial or other antigen related to α-galactosylceramide) to stimulate the immune response through the CD40L/CD40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e. synergistically due to the interaction, cross-talk and/or cross-stimulation of the glycolipid-CD1d pathway and TAA/ecdCD40L pathway. As a result, a potent immune response is induced against lipid target antigens as well as protein target antigens.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent applicationSer. No. 14/163,206 filed Jan. 24, 2014, which claims priority to U.S.Provisional Patent Application No. 61/776,875 filed on Mar. 12, 2013,the disclosures of which are both hereby incorporated herein byreference in their entireties.

FIELD OF THE INVENTION

The present invention relates to a vaccine composed of a complex of aglycolipid and theCD1d receptor combined with the TAA/ecdCD40L vaccine,for administration to an individual to simultaneously induce an innateimmune response against protein antigens of bacterial cells and toamplify the adaptive immune response induced by the TAA/ecdCD40L againstthe target associated antigen (TAA).

BACKGROUND OF THE INVENTION

NKT Cells, the CD1d System and Glycolipids from Marine Sponges,Bacterial Cells, and Human Tissues (1). NKT cells are defined by theexpression of a semi-invariant, CD1d-restricted, alpha-beta T cellreceptor (TCR). Most of these receptors are Vα14-Jα18/Vβ11 in structure.Human Vα24 NKT cells bind and react strongly to the CD1d receptor ondendritic cells, once this receptor is bound to certain glycolipids likealpha-galactosylceramide, the chemical structure of which is shown inFIG. 1A (originally isolated from the marine sponge: Agelas mauritianuswhich was first collected from the Okinawan Sea), and glycolipidsisolated from the cell wall of Sphingomonas (the chemical structures ofwhich are presented in FIG. 1B) which is a Gram-negative, LPS-negativemember of the alpha-proteobacteria class (1). A mixture of the CD1dreceptor mixed with either alpha-galactosylceramide, or the glycolipidsshown in FIG. 1B from Sphingomonas (both of which are comprised of asugar moiety linked to the ceramide lipid by an alpha glycolipid linkage(1) will induce activation of NKT cells through binding to theVα14-Jα18/Vβ11 receptor on human Vα24 NKT cells (1). Experimentaltesting shows that the injection of such glycolipids into mouse tumormodels induce tumor regressions and extends survival of tumor bearingmice (1). It is further noted that the glycospingolipids once bound tothe CD1d receptor on dendritic cells are responsible for the strongstimulation of NKT cells and their role in clearing infections (1).

Mixtures of CD1d with the glycosphingolipid iGb3 (the chemical structureof which is presented in FIG. 1C, which is found in mouse and humantissues (1), induces activation of human NKT cells, also through bindingof the Vα14-Jα18/Vβ11 receptor on human Vα24 NKT cells (1). The level onstimulation by iGb3 shown in FIG. 1C, in which a sugar moiety is linkedto ceramide through a beta linkage, is much weaker that that seen withthe glycolipids shown in FIGS. 1A and 1B, in which the sugar moiety islinked to the ceramide through an alpha linkage (1).

The CD1d receptor is a 37.713 kilodaltons (kDa) protein with 333 aminoacids: 18 amino acids in the signal sequence, 282 amino acids in theextracellular domain, 23 amino acids in the transmembrane domain and 10amino acids in the cytoplasmic domain (2). The aminoacid structure ofthe extracellular domain of the CD1d receptor (SEQ ID No. 1) is shown inFIG. 1D which is preferable although use of the entire CD1d protein (333aminoacids) is acceptable. Both in vitro and in vivo experiments showthat once any one of the glycolipids shown in FIGS. 1A-1C are mixed withthe entire CD1d receptor or ecdCD1d receptor (FIG. 1D), the complex thusformed displays a high affinity to the Vα14-Jα18/Vβ11 receptor on humanVα24 NKT cells.

Non Vα24 NKT cells which are CD1d restricted may be involved inautoimmune diseases (1). The CD1d system of MHC like molecules ondendritic cells (DCs) are thought to present lipid antigens to T cells.The combination of alpha-galactosylceramide like glycolipids (AGCLGL)with the CD1d on DCs binds to the mouse TCR of the NKT cells with adissociation constant (Kd) of 100 nM and with a Kd of 7 μM to the humanTCR (1). This results in the activation of expression of ligands such asCD40L on the NKTs, and the release from the NKT cells of Th1 and Th2cytokines and chemokines (see FIGS. 2A-2D). As a consequence of abacterial infection these cytokines are released from the activated NKTcells along with the binding of the CD40L of the activated NKT cells tothe CD40 receptor on the DCs and results in their activation (see FIGS.2A-2D).

CD1d and MHC Presentation Molecules on DCs.

DCs become activated through binding of external ligands to plasmamembrane receptors (e.g. the CD40 ligand/CD40 receptor) so as toincrease expression of Class I and Class II MHC for the presentation ofpeptide fragments of target protein antigens to CD8 effector T cells(see FIG. 3) and to increase the level of expression of surfacemolecules like CD1d for presentation of lipid antigens like, forexample, alpha-galactosylceramide (See FIGS. 2A-2D).

CD1d is expressed on DCs, cortical thymocytes, as well as B cells. CD1dis also found on hepatocytes in virally infected livers, as well asglial cells from inflamed tissues. CD1d is not found on any other cellsexcept at very low levels.

Bacterial Glycolipids and NKT Cells.

Alpha-galactosyldiacylglycerols extracted from Gram-negative LPSnegative organisms (such as Borrelia burgdorferi which causes Lymedisease) can directly stimulate NKT cells. Most of the evidenceindicates that NKT cells and their hVα24-Jα18 TCRs have the function ofbinding and recognizing α-galactosylceramide (AGC) like glycolipid(AGCLGL) ligands from bacterial cells so as trigger an innate likeimmune response (1) as well as an adaptive immune response.

AGC was first isolated from the marine sponge Agelas mauritanitus. Itwas shown that when AGC binds to the CD1d receptor on DCs, it can bindto the invariant antigen recognition receptor (IARR) of NKT cells andactivate them. AGCLCL antigens have been isolated from the followinginfectious agents which have been shown to bind CD1d resulting in thesubsequent binding of the ACLGL-CD1d combination to the IARR of NKT: (i)monoglycosylcderamides from Spongomonas species, (ii)phosphatidylinositol mannosides from Mycobacterium tuberculosis, (iii)lipophosphoglycan from Leishmania donovani. These AGCLGL moleculespresumably have similarities in structure to AGC. Applicant submits thatall infectious antigens, foreign antigens and/or self-antigens, of anykind or character, that carry glycolipid molecules that are similar instructure, fall within the confines of Applicant's invention.

Mechanism of the Immune Response to Invading Bacterial Cells Positivefor α-Galactosylceramide Like Glycolipid Ligands.

The invasion of a microbe positive for glycolipids similar toα-galactosylceramide leads to the binding of the α-galactosylceramidelike antigens (AGCLGL) to the CD1d molecule expressed on resting DCs.The formation of the α-galactosylceramide-CD1d or AGCLGL-CD1dcombination creates a structure which has a high binding affinity forthe hVα24-Jα18 TCRs of NKT cells.

Binding of Glycolipids to CD1d on DCs Leads to Activation of theCD40L/CD40 Receptor Pathway.

The binding of the α-galactosylceramide-CD1d or AGCLGL-CD1d combinationto the hVα24-Jα18 TCRs leads to activation of the NKT cells, withconsequent increase of the level of the immunostimulatory molecule, CD40ligand (CD40L), on the surface of the NKT cell (see FIGS. 2A-2D). Inaddition, the binding triggers the release from the NKT cells of largeamounts of Th1 like cytokines (interferon-γ, IL-12, and interferon-α),Th2 like cytokines (IL-4), and increased expression of the B7.1 and B7.2co-stimulatory molecules (1).

Interaction of NKT Cells and DCs. The expression of the CD40L on the NKTcells then leads to binding of the CD40L on the NKT cell surface to theCD40 receptor on the DCs (see FIG. 2), the very same DCs which have theα-galactosylceramide bound to their own CD1d receptor. Theseα-galactosylceramide-CD1d combinations on the DC bind to the hVα24-Jα18TCRs on the NKT cells. When the DC becomes activated by the CD40L of theactivated NKT, then these DCs migrate to the draining lymph nodes wherethey present their α-galactosylceramide-CD1d or AGCLGL-CD1d combinationsas well as their TAA to appropriate T and B cells to induce an adaptiveimmune response to the bacterial cell glycolipids and TAA.

Historical Summary of the Development of the TAA/ecdCD40L VaccinePlatform the Development of which the Applicant Participated as aCo-Inventor.

Previous Vaccines.

Vaccines have been described that include an adenoviral expressionvector encoding a fusion protein that includes a target associatedantigen (TAA) fused to the CD40 ligand (CD40L). See, e.g., U.S. PatentApplication Publication US 2005-0226888 (application Ser. No.11/009,533) titled “Methods for Generating Immunity to Antigen,” filedDec. 10, 2004.

The vaccine (see FIGS. 3A-3D) is based on the attachment of a fragmentof a TAA fused to the extracellular domain (ecd) of the potentimmunostimulatory signal CD40 ligand (CD40L). The TAA/ecdCD40L fusionprotein vaccine can be administered either as a TAA/ecdCD40L protein, oras an expression vector encoding the TAA/ecdCD40L such as virusincluding the adenoviral vector: Ad-sig-TAA/ecdCD40L vector, or otherviral vectors, or a plasmid DNA expression vector encoding theTAA/ecdCD40L protein (3-13). The vaccine can be also administered as anAd-sig-TAA/ecdCD40L vector prime followed in 7 and 21 days with scinjections of the TAA/ecdCD40L protein vaccine. This vaccine platformwas developed by the Applicant's laboratory (3-13) to overcome thefollowing problems: weak immunogenicity of the target antigens,qualitative or quantitative defects of CD4 helper T cells, defectiveresponse in immunodeficient individuals including the older agedpopulation due to diminished expression of CD40L in activated CD4 helperT cells, and/or low levels of presentation of target antigens on Class Ior II MHC in dendritic cells (DCs). The CD40L is important for theexpansion of antigen specific CD8 effector T cells and antigen specificB cells in response to vaccination.

Modes of Administration of TAA/ecdCD40L Vaccine.

There are four versions or modes of administration of this vaccine: 1.One in which the TAA/ecdCD40L transcription unit is embedded in areplication incompetent adenoviral vector (Ad-sig-TAA/ecdCD40L); 2. Onein which the vector is used as an initial priming injection, followed bytwo sc injections of the TAA/ecdCD40L protein; 3. One in which thevaccine consists solely of the TAA/ecdCD40L protein; and 4. One in whichthe TAA/ecdCD40L is inserted into a plasmid DNA expression vector. TheTAA is connected through a linker to the aminoterminal end of the ecd ofthe potent immunostimulatory signal CD40L.

Impact of Attachment of TAA to CD40L.

The attachment of fragments of the TAA to the CD40L accomplishes twothings: 1. The binding of the TAA/ecdCD40L protein to the CD40 receptoron the DCs as well as on the B cells and T cells, activating these cellsthereby promoting a potent immune response (3, 5, 7); 2. Once theTAA/ecdCD40L protein is engaged on the CD40 receptor of the DC, theentire TAA/ecdCD40L protein is internalized into the DC in a way thatallows Class I as well as Class II MHC presentation of the TAA (3, 7).

Activation of DCs by TAA/ecdCD40L Vaccine.

The activated TAA loaded DCs then migrate to the regional lymph nodes(3, 7) where they can activate and induce expansion of the TAA specificCD8⁺ effector T cells. The antigen specific CD8⁺ effector T cells becomeincreased in number in the lymph nodes (3, 7), and they then egress fromthe lymph nodes into the peripheral blood. The antigen specific CD8effector T cells exit the intravascular compartment and enter into theextra-vascular sites of inflammation or infection (10, 11, and 13). Inaddition to showing that this vaccine increases the levels of theantigen specific CD8⁺ effector T cells in the sites of inflammation orinfection (12), the Applicant's laboratory has shown that the activationand expansion of the TAA specific B cells by the TAA/ecdCD40L proteinincreases the levels of the TAA specific antibodies (see FIGS. 3A-3D)including neutralizing antibodies against viral antigens in the serum(10, 11 and 13).

SUMMARY OF THE INVENTION

Aspects of the invention are based on the co-administration of theTAA/ecdCD40L vaccine or expression vector with a complex formed betweeneither the CD1d receptor protein or the ecdCD1d receptor protein (FIG.1D) and an AGCLGL (FIG. 1A) vaccine. The addition of aα-galactosylceramide-CD1d or AGCLGL-CD1d complex with the TAA/ecdCD40Lvaccine or expression vector, further activates the CD40 receptor on DCsthereby promoting an increase in the magnitude of a cellular and humoralimmune response to the TAA. The ecd of the CD1d receptor is used in theAGCLGL-CD1d complex without the transmembrane domain or cytoplasmicdomain because all of the sequences necessary for the formation of theCD1d/AGCLGL complex are contained in the extracellular domain of theCD1d. The result and advantage of using both the TAA/ecdCD40L vaccineand the α-galactosylceramide-CD1d complex (or a related bacterial orother antigen related to α-galactosylceramide) to stimulate the immuneresponse through the CD40L/CD40 axis on the DCs, is that the magnitudeof the immune response induced against the TAA is increasedsignificantly over what could be achieved by administration of eitherthe fusion protein or vaccine alone. This is due to the cross-talk orcross-stimulation or interaction of the two glycolipid-CD1d andTAA/ecdCD40L DC pathways. As a result, a potent immune response isinduced against the protein target antigens. As will be addressed indetail below preferred embodiments of the invention, the vaccineadministrations may be done concurrently, or sequentially withinprescribed periods of time.

The following comprises several aspects of Applicant's invention as to anew method and/or composition of matter, any one or more of whichaspects are submitted to be an improvement over the prior art:

One aspect of the invention uses the vaccine combination of (i) acomplex formed by the CD1d receptor bound to a AGCLGL, and (ii) aTAA/ecdCD40L fusion protein, to respectively induce both an innate andadaptive immune response in an individual.

Another aspect of the invention uses a combination of a complex formedbetween an AGCLGL and CD1d, and the vaccine comprised of a TAA/ecdCD40Lfusion protein or an expression vector encoding the TAA/ecdCD40L fusionprotein, to induce both an innate and adaptive immune response in anindividual to the TAA and an innate immune response to the AGCLGL.

Yet another aspect of the invention takes advantage of the interactionof two classes of antigens and induce a increase in the adaptive immuneresponse against the TAA and an increase in the innate immune responseagainst both of these.

Further, other aspects of the invention gain the advantages of having adual component composition (whether given at the same or differenttimes), that can activate both the innate and adaptive immune responseto the TAA, by driving the human response to a new and extraordinarylevel. As is well known, the cells of the innate immune system play acrucial part in the initiation and subsequent direction of adaptiveimmune responses, as well as participating in the removal of pathogensthat have been targeted by an adaptive immune response.

As a consequence of the increased capability embodied in the makeup ofApplicant's unique dual component composition, it is an additionalobject of the current invention to leverage the natural responses of thehuman innate and adaptive immune response in such a manner to not onlypromote their inter-relationship to activate one's overall immuneresponse, but to engender crosstalk, interaction and/or stimulation thatpromotes a greater response to foreign pathogens in both time andpotency.

The above and other aspects and other embodiments are described indetail below.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1D show the structures of glycolipids (FIG. 1A-FIG. 1C) inwhich a ceramide lipid molecule is linked to a sugar, which when boundto the CD1d receptor or ecdCD1d receptor (FIG. 1D) are able to induceactivation of the NKT cells through binding of the Vα14-Jα18/Vβ11receptor on human Vα24 NKT cells (1).

FIGS. 2A-2D show prior art pathway steps involved in the induction of aninnate immune response which follows the appearance of a alphagalactosyl ceramide (AGC) like glycolipid as the result of a bacterialinfection: alpha galactosyl ceramide like glycolipid (AGCLGL).

FIGS. 3A-3D shows prior art pathway steps involved in the induction of aTAA specific adaptive immune response by administration of theTAA/ecdCD40L vaccine.

FIGS. 4A-4D shows cross talk, stimulation and/or interaction between theAGC-CD1d complex and TAA/ecdCD40L pathways and the cells of the innateand adaptive immune responses as a result of administration of theAGC-CD1d complex vaccine and the TAA/ecdCD40L vaccine, where multipleforms of cross talk, stimulation and/or interaction occur.

DETAILED DESCRIPTION OF THE INVENTION Definitions

The use of the terms “a” and “an” and “the” and similar referents in thecontext of describing the invention are to be construed to cover boththe singular and the plural, unless otherwise indicated herein orclearly contradicted by context. The terms “comprising,” “having,”“including,” and “containing” are to be construed as open-ended terms(i.e., meaning “including, but not limited to”) unless otherwise noted.Recitation of ranges of values herein are merely intended to serve as ashorthand method of referring individually to each separate valuefalling within the range, unless otherwise indicated herein, and eachseparate value is incorporated into the specification as if it wereindividually recited herein. All methods described herein can beperformed in a suitable order unless otherwise indicated herein orotherwise clearly contradicted by context.

As used herein, the terms “antigen” or “antigenic factors” refersbroadly to any antigen to which a human, mammal, bird or other animalcan generate an immune response. The terms “antigen” or “antigenicfactors” as used herein refers broadly to a molecule that contains atleast one antigenic determinant or epitope to which the immune responsemay be directed. The immune response may be cell-mediated, humoral orboth. As is well known in the art, an antigen may be protein,carbohydrate, lipid, or nucleic acid or any combinations of thesebiomolecules. As is also well known in the art, an antigen may benative, recombinant or synthetic. For example, an antigen may includenon-natural molecules such as polymers and the like. Antigens includeboth self-antigens and non-self antigens. As used herein, “antigenicdeterminant” (or epitope) refers to a single antigenic site on anantigen or antigenic factor; it is a minimal portion of a molecule thatrecognized by the immune system, specifically by antibodies, B cells orT cells. Antigenic determinants may be linear or discontinuous.

“Pharmaceutically acceptable” in the context of the present inventionmeans a pharmaceutical composition that is generally safe, non-toxic andbiologically acceptable for veterinary and human pharmaceutical use.Preferred compositions of this invention are intended for humans oranimals.

The phrase “an effective amount” in reference to administering thefusion protein or an expression vector encoding that protein is anamount that results in an increase in the immune response as measured byan increase in T cell activity or antibody production.

The TAA/ecdCD40L fusion protein—a mixture recited herein may beformulated with an adjuvant to enhance the resulting immune response. Asused herein, the term “adjuvant” in the context of the instant inventionmeans a chemical that, when administered with the expression vector orthe fusion protein, enhances the immune response. An adjuvant isdistinguished from a carrier protein in that the adjuvant is notchemically coupled to the antigen. Adjuvants are well known in the artand include, but not limited to, mineral oil emulsions (U.S. Pat. No.4,608,251) such as Freund's complete or Freund's incomplete adjuvant(Freund, Adv. Tuberc. Res. 7:130 (1956); Calbiochem, San Diego Calif.),aluminum salts, especially aluminum hydroxide or ALHYDROGEL (approvedfor use in humans by the U.S. Food and Drug Administration), muramyldipeptide (MDP) and its analogs such as [Thr¹]-MDP (Byersand Allison,Vaccine 5:223 (1987)), monophosphoryl lipid A (Johnson et al., Rev.Infect. Dis. 9:S512 (198)), and the like.

The term “vector” as used in this application contains a transcriptionunit (also known as an “expression vector”). It encompasses both viraland non-viral expression vectors that when administered in vivo canenter target cells and express an encoded protein. Viral vectors haveevolved means to overcome cellular barriers and immune defensemechanisms. Viral vectors suitable for in vivo delivery and expressionof an exogenous protein are well known in the art and include adenoviralvectors, adeno-associated viral vectors, retroviral vectors, vacciniavectors, pox vectors, herpes simplex viral vectors, etc. Viral vectorsare preferably made replication defective in normal cells. For example,see U.S. Pat. Nos. 6,669,942; 6,566,128; 6,794,188; 6,110,744 and6,133,029.

On the other hand, non-viral gene carriers consistently exhibitsignificantly reduced transfection efficiency as they are hindered bynumerous extra- and intracellular obstacles. Non-viral vectors for genedelivery comprise various types of expression vectors (e.g., plasmids)which are combined with lipids, proteins and other molecules (orcombinations of thereof) in order to protect the DNA of the vectorduring delivery. Fusigenic non-viral particles can be constructed bycombining viral fusion proteins with expression vectors as described.Kaneda, Curr Drug Targets (2003) 4(8):599-602. Reconstituted HVJ(hemagglutinating virus of Japan; Sendai virus)-liposomes can be used todeliver expression vectors or the vectors may be incorporated directlyinto inactivated HVJ particles without liposomes. See Kaneda, Curr DrugTargets (2003) 4(8):599-602. DMRIE/DOPE lipid mixture is useful as avehicle for non-viral expression vectors. See U.S. Pat. No. 6,147,055.Polycation-DNA complexes also may be used as a nonviral gene deliveryvehicle. See Thomas et al., Appl Microbiol Biotechnol (2003)62(1):27-34. The vector can be administered parenterally, such asintravascularly, intravenously, intra-arterially, intramuscularly,subcutaneously, or the like. Administration can also be orally, nasally,rectally, transdermally or aerosol inhalation. The vectors may beadministered as a bolus, or slowly infused. The vector is preferablyadministered subcutaneously.

The term “transcription unit” as used herein in connection with anexpression vector means a stretch of DNA, that is transcribed as asingle, continuous mRNA strand by RNA polymerase, and includes thesignals for initiation and termination of transcription. For example, inone embodiment, a transcription unit of the invention includes nucleicacid that encodes from 5′ to 3′ a secretory signal sequence, aninfluenza antigen and CD40 ligand. The transcription unit is in operablelinkage with transcriptional and/or translational expression controlelements such as a promoter and optionally any upstream or downstreamenhancer element(s). One useful promoter/enhancer is the cytomegalovirus(CMV) immediate-early promoter/enhancer. See U.S. Pat. Nos. 5,849,522and 6,218,140.

The term “secretory signal sequence” (also known as “signal sequence,”“signal peptide,” leader sequence, “or leader peptide”) as used hereinrefers to a short peptide sequence, generally hydrophobic in charter,including about 20 to 30 amino acids that is synthesized at theN-terminus of a polypeptide and directs the polypeptide to theendoplasmic reticulum. The secretory signal sequence is generallycleaved upon translocation of the polypeptide into the endoplasmicreticulum. Eukaryotic secretory signal sequences are preferred fordirecting secretion of the exogenous gene product of the expressionvector. A variety of suitable such sequences are well known in the artand include the secretory signal sequence of human growth hormone,immunoglobulin kappa chain, and the like. In some embodiments, theendogenous tumor antigen signal sequence also may be used to directsecretion.

The term “CD40 ligand” (CD40L) as used herein refers to a full length orportion of the molecule known also as CD154 or TNF5. CD40L is a type IImembrane polypeptide having a cytoplasmic domain at its N-terminus, atransmembrane region and then an extracellular domain (ecd) at itsC-terminus. Unless otherwise indicated the full length CD40L isdesignated herein as “CD40L,” “wtCD40L” or “wtTmCD40L.” The nucleotideand amino acid sequence of CD40L from mouse and human is well known inthe art and can be found, for example, in U.S. Pat. No. 5,962,406. Also,included within the meaning of CD40 ligand are variations in thesequence including, but not limited to, conservative amino acid changesand the like which do not alter the ability of the ligand to elicit animmune response in conjunction with the fusion protein of the invention.

The term “antibody” as used herein (includes but is not limited toneutralizing antibodies) refers, for example, to antibodies that block,neutralize or otherwise act against the infectious foreign antigen.

The term “linker” as used or employed in this application with respectto the transcription unit of the expression vector refers to one or moreamino acid residues between the carboxyl terminal end of the antigen andthe amino terminal end of CD40 ligand. The composition and length of thelinker may be determined in accordance with methods well known in theart and may be tested for efficacy. (See, e.g. Arai et al. ProteinEngineering, Vol. 4, No. 8, 529-532, August 2001). In certainembodiments of the present invention, the linker is from about 3 toabout 15 amino acids long, more preferably from about 5 to about 10amino acids long. However, longer or shorter linkers may be used or thelinker may not be used at all. Longer linkers may be up to about 50amino acids, or up to about 100 amino acids. One example of a linkerwell known in the art is a 15 amino acid linker consisting of threerepeats of four glycines and a serine (i.e., [Gly₄Ser₃)].

The term “TAA” recited herein refers to a target associated antigen,which may, for example, be a viral antigen, a bacterial antigen, a tumorantigen, etc.

The term “crosstalk” or “cross-stimulation” or “stimulation” or“interaction”, as a result of the administration of an AGC likeglycolipid (AGCLGL) complexed with an CD1d receptor along with theTAA/ecdCD40L vaccine (see FIG. 4) as used herein means that the CD40L onthe AGCLGL-CD1d receptor activated NKT cells stimulates the DCs whichare presenting TAA as well as glycolipids. In addition, it means thatthe release of cytokines from the NKT cells activated by theadministration of an AGC like glycolipid (AGCLGL) complexed with an CD1dreceptor along with the TAA/ecdCD40L vaccine stimulates both pathways byinducing the release of cytokines from both the NKT cells as well as theDCs that further promote and further amplify the immune response inducedby the TAA/ecdCD40L vaccine. Biological crosstalk generally refers toinstances in which one or more components of one signal transductionpathway affect another. This can be achieved through a number of wayswith the most common form being crosstalk between proteins of signalingcascades. In these signal transduction pathways, there are often sharedcomponents that can interact with either pathway.

The terms “pathway” or “biological pathway” as used herein is a seriesof actions among molecules in a cell that leads to a certain product ora change in a cell. Such a pathway can trigger the assembly of newmolecules, such as a fat or protein. Cells are constantly receiving cuesfrom both inside and outside the body, which are prompted by such thingsas injury, infection, stress or even food. To react and adjust to thesecues, cells send and receive signals through biological pathways. Themolecules that make up biological pathways interact with signals, aswell as with each other, to carry out their designated tasks.

AGC was first isolated from the marine sponge Agelas mauritanitus. Itwas shown that when AGC binds to the CD1d receptor, it can bind to theinvariant antigen receptor (IARR) of NKT cells and activate them. Theterm “AGC” means α-galactosylceramide. However, there are equivalentmolecules that have similarities in structure to AGC (i.e. AGCLGL). Forexample, antigens have been isolated from the following infectiousagents and been shown to bind CD1d and then to bind the IARR of the NKT:a. monoglycosylcderamides from Spongomonas species, b.phosphatidylinositol mannosides from Mycobacterium tuberculosis, and c.lipophosphoglycan from Leishmania donovani.

List of Abbreviations

Some of the abbreviations used in the instant application:

Ad—Adenoviral

AGC—α-galactosylceramideCD40L—CD40 ligandCD1d—non-classical MHC class 1b molecule

CMV—Cytomegalovirus

DCs—dendritic cellsecd—extracellular domainIARR—invariant antigen recognition receptorSC—subcutaneous or subcutaneouslySig—signal sequence

TAA—Target Associated Antigen

Applicant's inventive composition of a complex component and a vaccinecomponent, among other features, creates an anti-bacterial compositionwhich is (i) very potent and induces a robust immune response againstboth peptide and glycolipid bacterial antigens, (ii) reduces thevirulence of the bacterial cell, and (iii) prevents progression of anexisting bacterial cell infection.

A chimeric α-galactosylceramide like glycolipid (AGCLGL) shown in FIG.1A is complexed ex vivo with the CD1d receptor or ecdCD1d receptor (FIG.1D) produced as recombinant biological. This complex is then preferablyadministered subcutaneously (sc) or intratumorally along with a vaccinecomprised of a target associated protein antigen (TAA) fused through alinker to the ecd of the CD40L. An example of a method of forming thecomplex between alpha galactosylceramide (FIG. 1A) and the CD1d receptoris as outlined by the following steps, adapted by the method of Sriramet al (14). Lyophilized powder of alpha galactosyl ceramide is dissolvedin 0.05% Tween-20 and then various dilutions are made in phosphatebuffered saline (pH=7.4) with sonication. Dimeric CD1d-IgG which waspurchased from Pharmingen, was mixed in different ratios of the solutionof alpha galactosylceramide (as shown in FIG. 1A) and incubatedovernight at 37 degrees C. These complexes were either added to NKTtarget cells in vitro or were injected subcutaneously into areas of testmice that had been injected 10 days earlier with adenoviral vectors orplasmid expression vectors which encode the TAA/ecdCD40L vaccine.

The TAA/ecdCD40L expression vector is made by the following steps.Synthesize a 30-40 AA long target associated antigen connected at itscarboxylterminal end to the aminoterminal end of a 10 amino acid linkerwhich is in turn attached at its carboxylterminal end to theaminoterminal end of the ecdCD40L. This TAA/ecdCD40L transcription unitis inserted into a plasmid expression vector downstream of a strongtranscriptional promoter (e.g. CMV) by standard techniques.

The interaction of the AGCLGL-CD1d receptor activated NKT cells with thedendritic cells (DCs) through the CD40L/CD40 receptor axis that isactivated by this combination, will not only trigger a massive cytokinerelease and activation of multiple components of the innate immuneresponse but also induce an increased and robust cellular and humoraland cellular adaptive immune response against glycolipid antigens,protein antigens, and virulence proteins of the bacterial cell.

Pathways—the Biological Pathways of AGC-CD1d and TAA/ecdCD40L—theAGC-CD1d or AGCLGL-CD1d Pathway—

In FIG. 2 there is depicted the steps in the induction of an innateimmune response which follows the appearance of a glycolipid: alphagalactosyl ceramide (AGC) or alpha galactosyl ceramide like glycolipid(AGCLGL) as a result of a bacterial infection:

Step 2a: Appearance of the alpha galactosyl ceramide (AGC) or AGCLGL asthe result of a bacterial infection at the initial site of infectionwhich is usually near the surfaces of the body in tissues which are richin dendritic cells (DCs) as shown in FIG. 2A.

Step 2b: Binding of the AGC or AGCLGL complexed to CD1d on DCs to theinvariant antigen recognition receptor (IARR) of the NKT cell whichactivates the NKT cell (as shown in FIG. 2B-C).

Step 2c: Activation of NKT cells results in a. release of cytokinesstimulatory to the induction of an immune response (e.g. IL-12 or gammainterferon or many others) from the NKT cell, and b. appearance of theCD40 ligand (CD40L) on the surface of the NKT cell, as shown in FIG. 2B-C.

Step 2d: Binding of the CD40L on the NKT cell to the CD40 receptor onthe DCs which results in activation of the DCs as shown in FIG. 2B-C.

Step 2d: Activation of NKT cells results in further release of cytokinesstimulatory of an adaptive and innate immune response (e.g. IL-12), asshown in FIG. 2B-C.

Step 2e: The cytokines released bind to and activate the followingcells: monocytes, DCs, B cell lymphocytes, CD4 helper T cells, and CD8+effector T cells resulting in the appearance of Class I and Class II MHCon the surface of the DCs, the appearance of intercellular cytoadhesionmolecules like CD88 and CD86 on the surface of the DC, and theactivation of the T cell and B cell lymphocytes (see FIG. 2D).

The TAA/ecdCD40L Pathway—

In FIG. 3 there is depicted the steps involved in the induction of a TAAspecific adaptive immune response by administration of the TAA/ecdCD40Lvaccine.

Step 3a: Administration of the TAA/ecdCD40L vaccine either as theTAA/ecdCD40L protein, or as an expression vector which carries atranscription unit which encodes the TAA/ecdCD40L protein which theninduces the in vivo release of the TAA/ecdCD40L as shown in FIG. 3A-B.

Step 3b: The TAA/ecdCD40L fusion protein is taken up into the DC by CD40receptor mediated endocytosis in a way that promotes presentation offragments of TAA on both Class I and Class II MHC (see FIG. 3C).

Step 3c: Binding of the TAA/ecdCD40L fusion protein (at the C-ter whichcontains the ecdCD40L) to the CD40 receptor on DCs, CD8+ effector Tcells, B cells, and CD4 helper T cells which activates the DCs (inducesexpression of IL2, IL2 receptor, CD88 and CD86 on DCs), increasesexpression of CD40L on the CD4 helper T cells, and facilitates expansionof TAA specific CD8+ effector T cells and B cells, if they areresponding to TAA which are independently presented on Class I or ClassII MHC (respectively) on DCs, as shown in FIG. 3D.

Step 3d: Presentation of TAA fragments on Class I and Class II MHC onDCs as shown in FIG. 3D.

Step 3e: Activation and induction of expansion of the TAA specific Bcells and TAA specific CD8+ effector T cells, as shown in FIG. 3D.

Step 3f: Increase in the levels of TAA specific antibodies in theintravascular space and TAA specific CD8+ effector T cells at sites ofinfection or inflammation (cancer), as shown in FIG. 3D.

Cross Talk/Stimulation/Interaction Between the AGC-CD1d or AGCLGL-CD1dand TAA/ecdCD40L Pathways

In FIG. 4 there is depicted as a result of simultaneous administrationof the AGC-CD1d or AGCLGL-CD1d complex and the TAA/ecdCD40L vaccine, theinduction of the following forms of cross talk between cells of theinnate and adaptive immune response which amplifies the magnitude of theimmune response otherwise induced by administration of the TAA/ecdCD40Lvaccine alone.

4a. In FIG. 4A, is shown the state of the NKT cell and the DC prior tothe administration of a vaccine comprised of an AGC like glycolipidcomplexed with an CD1d receptor along with the TAA/ecdCD40L vaccine.Note that no CD40L is present on the surface of NKT cells, and thatthere is no cytokine release from either the DC or the NKT cell.

4b. In FIG. 4B, is shown the co-administration of a complex of an AGClike glycolipid with an CD1d receptor (in the circle) together with theTAA/ecdCD40L fusion protein vaccine to a human subject's arm. Althoughin FIG. 4B, the complex of a AGCLGL with a CD1d receptor and theTAA/ecdCD40L fusion protein, are depicted administered together, asnoted in FIG. 4C (in 4c below) the complex of a AGCLGL with a CD1dreceptor and the TAA/ecdCD40L fusion protein vaccine, are shown injectedseparately.

4c: In FIG. 4C is shown that the administration of an AGC likeglycolipid (see, for example, in FIG. 1A) complexed with an CD1dreceptor or ecdCD1d receptor (see SEQ ID No. 1 in FIG. 1D), along withthe TAA/ecdCD40L fusion protein vaccine which results in the binding ofthe glycolipid CD1d receptor complex to the IARR of the NKT cells withthe resultant activation of the NKT cells which results in theappearance of CD40L on the surface of the NKT cell and the release ofcytokines from NKT cells. This in turn results in the binding of theCD40L on the NKT cell to the CD40 receptor on the DC as well as the NKTcell cytokine release stimulation of the DCs which induces a release ofcytokines from them as well as the appearance of a family of cytoadesionmolecules of the DCs which further promote the development of anadaptive immune response as a result of the administration of theTAA/ecdCD40L. Finally, as shown in FIG. 4D, the result of the inductionof the cytokine release from both NKT cells and DCs, as well as theengagement of the CD40 receptor on DCs by the CD40L on the activated NKTcells as well as the engagement of the CD40 receptor on DCs, B cells andT cells by the CD40L in the TAA/ecdCD40L vaccine, is that the activatedand antigen loaded DCs present the TAA to B cells and T cells which havealready been primed to respond by the prior cytokine release and CD40Lstimulation.

This results in enhancement of the response of TAA specific B cells andCD8+ effector T cells to TAA presented by DCs by the cytokines releasedfrom the activation of the NKT cells (see FIG. 4D).

The administration of both the AGCLGL-CD1d receptor complex and theTAA/ecdCD40Lvaccine, lead to amplification of the NKT response againstthe bacterial cells, and amplification of the induction of a robustinnate as well as adaptive humoral and cellular immune response againstthe infectious agent.

Delivery of the Glycolipid-CD1d and TAA/ecdCD40L Vaccines InducesCross-Talk Between NKT Cells and DCs.

The AGCLGL-CD1d receptor complex is delivered sc along with theTAA/ecdCD40L vaccine (see FIG. 4B). The glycolipid-CD1d complex willinduce an innate immune response to a bacterial glycolipid antigen (seeFIG. 2) and amplify the magnitude of the TAA/ecdCD40L vaccine inducedadaptive immune response to a peptide antigen (see FIG. 3C). As aconsequence of cross-talk or interaction between these two parallelpathways which intersect at the CD40 receptor on the DC, there will beadditional stimulation (i.e. synergistic and robust) of the immuneresponse to both the bacterial glycolipids and TAA peptides. Crosstalkor interaction means that the CD40L on the NKT cells as well as theTAA/ecdCD40L vaccine stimulates the DCs which are presenting TAA as wellas glycolipids (see FIG. 4C). In addition, the release of cytokines fromthe NKT cells activated by the DCs carrying glycolipids on their CD1dreceptor as well as the release of cytokines from the DCs bound to theTAA/ecdCD40L vaccine stimulates both pathways (see FIG. 4D).

The t immune response to glycolipid and or peptide may be inducedindependent of the order of the administration. If one administers theglycolipid-CD1d receptor complex first and then after a time intervaladminister the TAA/ecdCD40L, there will be an amplification of theimmune response.

If one administers the TAA/ecdCD40L first and then after a time intervalthe glycolipid-CD1d receptor complex, then there will be anamplification of the immune response.

If one administers both at the same time, then the magnitude of theimmune response will be higher than if either is administered alone.

This is due to the stimulation of the DCs by engagement of the CD40receptor by CD40L from two pathways instead of from just one. Inaddition, cytokine release is from the activated NKT cells (in theAGCLGL-CD1d pathway) as well as from the DCs which are activated in theTAA/ecdCD40L pathway.

Details of Cross Talk/Stimulation/Interaction Between NKT Cells and DCs.

The cross-talk comprises of the release of cytokines and points ofstimulation as follows:

-   -   a) The stimulation of the NKT cells by binding of the        AGCLGL-CD1d receptor preformed complex.    -   b) The release from the NKT cells of a high level of cytokines        and chemokines which stimulate both the AGCLGL-CD1d pathway as        well as the TAA/ecdCD40L pathway. This NKT dependent cytokine        release is added to that already induced from the DCs in the        TAA/ecdCD40L pathway. These cytokines stimulate DCs, B cells, T        cells, and monocytes.    -   c) The induction of expression of CD40L on the NKT cells as a        result of the binding of the AGCLGL-CD1d receptor complex to the        invariant antigen recognition receptor on the NKT cells.    -   d) The activation of the DCs by binding of the CD40L of the NKT        cells to the CD40 receptor on DCs as well as the activation of        the DCs by binding of the CD40 receptor by the TAA/ecdCD40L        vaccine thus creating a robust stimulation of the DCs by CD40L        from two different pathways.    -   e) All of these events leading to CD40L activation of the DCs        and stimulation of all the cells of the immune response released        from activated NKT cells as well as DCs by the dual component        complex-vaccine strategy.

The combination of the AGCLGL-CD1d receptor delivered as pre-formedcomplex, and the TAA/ecdCD40L vaccine fusion molecule delivered as aplasmid DNA or viral expression vector will act to stimulate the CD40receptor axis for the presentation of antigens of bacterial cells. TheTAA/ecdCD40L can be administered as a chimeric protein, or as expressionvectors which encode the TAA/ecdCD40L. Because both of these moleculeswill trigger directly or indirectly the activation of the CD40 axis, themagnitude of the immune response is increased as a consequence of theco-administration.

In the above discussion, the TAA referred to are from bacterial cells.But the same strategy would apply to foreign antigens on otherinfectious agents such as viruses, as well as tumor cells.

The steps involved in each of the AGCLGL-CD1d receptor complex andTAA/ecdCD40L pathways are summarized in FIGS. 2-3. In FIG. 4 issummarized the consequences of the administration of the AGCLGL-CD1dcomplex along with the TAA/ecdCD40L vaccine on stimulating cross talkbetween NKT cells and DCs resulting in an increase in the magnitude ofthe immune response induced by the TAA/ecdCD40L vaccine.

Advantages of the NKT Glycolipid-CD1d Complex-TAA/CD40L-VaccineStrategy.

The co-administration of the complex and vaccine components will notonly trigger a massive cytokine release and activation of multiplecomponents of the innate immune response against the TAA as well asagainst the glycolipid of the bacterial cell but also induce a cellularand humoral adaptive immune response against the surface proteins andprotein virulence factors of the bacterial cell.

Up to the present time, no vaccine strategy such as Applicant's has beendeveloped which could induce simultaneously an immune response againstbacterial lipids as well as protein antigens. In addition, this is thefirst strategy which utilizes dual stimulation of the CD40L/CD40receptor pathway. Thus, not only will there be induction of an immuneresponse to the peptide as well as the lipid antigens of the bacterialcell, but the use of the stimulators of the NKT cell and the dendriticcell will produce amplification of the magnitude of the activation ofthe immune response through the CD40L/CD40 receptor pathway.

Embodiments are set forth within the claims that follow.

REFERENCES

-   1. Bendelac A, Savage P G, and Teyto L. The biology of NKT Cells.    Annual Review of Immunology 25: 297-336, (2007).-   2. Zhang P, Li D, Stewart-Jones G, Shao X, Zhang Y X, Chen Q G, Li Y    J, He Y W, Xy X B and Xhang H T. Immunology 128: 500-510, (2009).-   3. Zhang, L, Tang, Y, Akbulut H, Zelterman D, Linton P-J, and    Deisseroth, A. An adenoviral vector cancer vaccine that delivers a    tumor-associated antigen/CD40-ligand fusion protein to dendritic    cells. PNAS, 100: 15101-15106, (2003).-   4. Akbulut, H, Tang, Y, Maynard J, Zhang L, Pizzorno G, and    Deisseroth, A. Vector targeting makes 5-fluorouracil chemotherapy    less toxic and more effective in animal models of epithelial    neoplasms. Clin Cancer Res 10: 7738-7746, (2004).-   5. Tang, Y, Zhang, L, Yuan, J, Akbulut H, Maynard J, Linton P-J, and    Deisseroth, A. Multistep process through which adenoviral vector    vaccine overcomes anergy to tumor-associated antigens. Blood, 104:    2704-2713, (2004).-   6. Akbulut H, Tang Y C, Akbulut K G, Maynard J, Zhang L,    Deisseroth A. Antitumor immune response induced by i.t. injection of    vector activated dendritic cells and chemotherapy suppresses    metastatic breast cancer. Mol Cancer Ther 5:1975-1985, (2006).-   7. Tang Y C, Maynard J, Akbulut H, Fang X M, Zhang W W, Xia X Q,    Koziol J, Linton P-J, and Deisseroth A. Vaccine which overcomes    defects acquired during aging and cancer. Journal of Immunology    177:5697-5707, (2006).-   8. Tang Y, Akbulut H, Maynard J, Zhang L, Petersen L, and    Deisseroth A. Vaccine strategies for cancer and infectious diseases    in the elderly. Gene Therapy, Eds. Takenori Ochiai, Hideaki Shimada,    and Masatoshi Tagawa, Published by Japanese Ministry of Education    and Science, pp. 78-85, (2007).-   9. Akbulut H, Akbulut K G, Tang Y C, Maynard J and Deisseroth A.    Chemotherapy targeted to cancer tissue potentiates antigen specific    immune response induced by vaccine for In vivo antigen loading and    activation of dendritic cells. Molecular Therapy, 10:1753-1760,    (2008).-   10. Tang, Y C, Linton, P J, Thoman M, and Deisseroth A. Symposium in    Writing: Vaccine for infections and cancer. Cancer Immunology and    Immunotherapy, 58: 1949-1957, (2009).-   11. Han T H, Tang, Y C, Park Y H, Petersen L, Maynard J, Li P C, and    Deisseroth A. Ad-sig-BcrAb1/ecdCD40L vector prime-BcrAb1/ecdCD40L    protein boost vaccine for P210Bcr-Abl protein. Bone Marrow    Transplantation, (2009).-   12. Akbulut H, Tang Y, Akbulut K G, Maynard J, and Deisseroth A.    Addition of adenoviral vector targeting of chemotherapy to the    MUC-1/ecdCD40L VPPP vector prime protein boost vaccine prolongs    survival of mice carrying growing subcutaneous deposits of Lewis    lung cancer cells. Gene Therapy, 17: 1333-1340, (2010).-   13. Deisseroth A, Tang Y, Zhang L, Akbulut H, and Habib N.    TAA/ecdCD40L adenoviral prime-protein boost vaccine for cancer and    infectious diseases. Cancer Gene Therapy 20: 65-69, (2013).-   14. Sriram V, Du W J, Gervay-Hague J, and Brutkiewicz R R. Cell wall    glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific    ligands for NKT cells. European Journal of Immunology 35: 1692-1701,    (2005).

1. A method for activating an individual's innate and adaptive immuneresponse by the administration to the individual of a two componentcomposition, said composition comprising: (i) a first componentcomprising an effective amount of a complex comprising an alphagalactosyl ceramide like glycolipid (AGCLGL) bound to the CD1d protein(AGCLGL-ecdCD1d) to promote activation of NKT cells and activation of anindividual's dendritic cells, and T cell lymphocytes; and (ii) a secondcomponent comprising an effective amount of the fusion protein vaccinecomprising a target associated antigen fused to the ecd of the CD40L(TAA/CD40L) configured to promote activation of dendritic cells andactivation and expansion of TAA specific cytotoxic CD8+ effector T cellsand TAA B cells inducing the release of TAA specific antibodies; (iii)wherein said administration of said composition is adapted to promoteinteraction through a CD40L/CD40 axis on dendritic cells.
 2. The methodaccording to claim 1 wherein said two component administrations areapplied concurrently so as to promote crosstalk between NKT cells andthe following cell types: dendritic cells, B cell lymphocytes and T celllymphocytes.
 3. The method according to claim 1, wherein each of saidtwo components is administered before or after the other to promote animmune response against the glycolipid of the AGCLGL-CD1d receptorcomplex or the TAA of the TAA/ecdCD40L vaccine.
 4. The method accordingto claim 3 wherein said prescribed period of time in between the twocomponent injections is at least one week.
 5. The method according toclaim 4 wherein said prescribed period of time is at least two weeks. 6.The method according to claim 4 wherein said prescribed period of timeis at least three weeks.
 7. The method of claim 1 whereby saidcomponents are mixed together and applied in a single administration. 8.The method of claim 1 wherein said components are separate and appliedin separate administrations.
 9. The method of claim 1 wherein saidcomposition is administered in a treatment or preventative mode.
 10. Themethod of claim 1 wherein said fusion protein vaccine is an adenoviralexpression vector encoding the TAA/ecdCD40L.
 11. The method of claim 1wherein said fusion protein vaccine is a plasmid DNA expression vectorencoding the TAA/ecdCD40L protein.
 12. A composition comprising twocomponents for administration to an individual, comprising: (i) a firstcomponent complex of a AGCLGL with a CD1d receptor; and, (ii) a secondcomponent TAA/ecdCD40L fusion protein.
 13. A composition according toclaim 12, wherein said complex comprises an effective amount AGCLGL-CD1dreceptor for promoting activation of NKT cells, and said fusion proteincomprises an effective amount of TAA/ecdCD40L for promoting activationof cytotoxic CD8+ effector T cells.
 14. A composition according to claim13 wherein administration of said composition, is adapted to generate inthe individual an interaction through a CD40L/CD40 axis on dendriticcells.
 15. A composition according to claim 13 wherein said TAA in saidfusion protein is connected to the aminoterminal of the ecd of saidCD40L.
 16. An anti-bacterial composition adapted to induce anindividual's innate and adaptive immune response against both peptideand glycolipid bacterial antigens, said composition comprising: (i) aAGCLGL bacterial antigenic fragment complexed ex vivo with a CD1dreceptor, produced as recombinant biological; (ii) a target associatedprotein antigen (TAA) fused through a linker to the ecd of theaminoterminal a CD40L protein defining a fusion protein vaccine; and,wherein said composition is adapted to stimulate the immune responsethrough the CD40L/CD40 axis on dendritic cells and to induce both aninnate and an adaptive immune response.
 17. A composition according toclaim 16 wherein the combination of said recombinant biological and saidfusion protein, are adapted to promote cross-stimulation in theirrespective biological pathways.
 18. A composition according to claim 16wherein said TAA is connected to the aminoterminal of the ecd of theCD40L.
 19. The composition of claim 16 wherein said fusion proteinvaccine is an adenoviral expression vector encoding the TAA/ecdCD40L.20. The composition of claim 16 wherein said fusion protein vaccine is aplasmid DNA expression vector encoding the TAA/ecdCD40L protein.
 21. Avaccine composition for promoting an individual's innate and adaptiveimmune response against a foreign antigen, at least in part through theCD40/CD40L axis on dendritic cells, comprising: (i) a complex of aAGCLGL with a CD1d receptor; (ii) a TAA/ecdCD40L fusion protein vaccine;and, wherein said complex and fusion protein are configured to promotecrosstalk between biological pathways generated by AGCLGL-CD1d receptorand TAA/ecdCD40L vaccine, to help amplify the individual's immuneresponse against the foreign antigen.